Home
Companies
Incyte Corporation

Incyte Corporation

Company

Also known as: Incyte

Company Profile

Incyte is a U.S. multinational pharmaceutical company headquartered in Wilmington, Delaware. The company develops and manufactures prescription biopharmaceutical medicines across oncology, inflammation, and autoimmunity.

Website: https://www.incyte.com
Headquarters: Wilmington, Delaware, USA
Founded: 2002
Stock Ticker: NASDAQ:INCY

Related News

FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth

Jun 23, 2026

The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.

Incyte starts pivotal Dawn-03 trial of INCB161734 in KRAS G12D-mutant pancreatic cancer

Apr 23, 2026

Incyte has started the phase 3 Dawn-03 trial of INCB161734 plus chemotherapy in first-line KRAS G12D-mutant pancreatic cancer. The move comes while the phase 1 study remains halted in four European countries after pneumonitis cases, including one grade 5 event.

Adagene and Incyte Launch Clinical Collaboration for Muzastotug Combination in Colorectal Cancer

Apr 02, 2026

Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.

Myelofibrosis Pipeline Expands with Over 40 Candidates from 35+ Companies

Mar 25, 2026

The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.

FDA Approves CAR-T Therapy for Marginal Zone Lymphoma, New Myeloma Drug Advances to Phase 2

Mar 24, 2026

The FDA has approved Bristol Myers Squibb's CAR-T therapy Breyanzi for relapsed/refractory marginal zone lymphoma, while a novel multiple myeloma drug candidate DTP3 advances to Phase 2 trials after showing promising early results. Both developments represent significant progress in blood cancer treatment, with the marginal zone lymphoma approval based on a 95.5% response rate and the myeloma drug demonstrating selective cancer cell killing without toxicity.

Incyte Outlines Post-Jakafi Growth Strategy at Barclays Conference

Mar 21, 2026

Incyte executives presented a post-Jakafi growth strategy at the Barclays conference, outlining four product launches and pipeline progress in hematology, immunology, and solid tumors ahead of Jakafi's loss of exclusivity in 2029.

Cancer Pipeline Reports Show 45+ CSCC, 70+ Liver Cancer, and Multiple HCC Therapies in Development

Mar 20, 2026

DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.

Syndax Pharmaceuticals Expands Revuforj Access and Reports Strong Commercial Performance

Mar 19, 2026

Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.

Incyte's Zynyz Faces FDA Setback in Lung Cancer, Gains European Approval for Anal Cancer

Mar 07, 2026

Incyte received a Complete Response Letter from the FDA for Zynyz in lung cancer due to third-party manufacturing issues, while the EMA recommended approval for the drug in anal cancer treatment based on Phase 3 trial data.

PD-1 and PD-L1 Inhibitors Market Expands with 200+ Drugs in Development Across 180+ Companies

Feb 19, 2026

A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07765836	Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC	NOT_YET_RECRUITING	PHASE2
NCT07731789	Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma	NOT_YET_RECRUITING	PHASE2
NCT07623200	A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia	RECRUITING	PHASE3
NCT07588139	A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants	RECRUITING	PHASE1
NCT07559474	A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment	RECRUITING	PHASE1
NCT07559396	A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease	RECRUITING	PHASE1
NCT07548983	Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation	RECRUITING	PHASE1
NCT07522073	A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma	RECRUITING	PHASE3
NCT07511062	Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML	NOT_YET_RECRUITING	PHASE1
NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	NOT_YET_RECRUITING	PHASE2